



PRESS RELEASE

Indoco Q4 revenues at ₹ 3,411 mn

Mumbai, May 22, 2025: During the fourth quarter of FY 2024-25, revenues of Indoco Remedies are at ₹ 3,411 mn, as against ₹ 4,351 mn, same quarter last year. EBIDTA for the quarter is at ₹ 35 mn, compared to ₹ 574 mn, same quarter last year.

For the year, revenues are at ₹ 14,948 mn, as against ₹ 17,620 mn, same period last year. EBIDTA to net sales for the period is 8.6 % at ₹ 1,280 mn, compared to 14.6 % at ₹ 2,580 mn, same period last year. Profit After Tax are at ₹ (-)87 mn, compared to ₹ 1,166 mn, same period last year.

Commenting on the results, Ms. Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “While this has been a challenging year for Indoco, there are several optimistic triggers which gives us confidence for a better future, both in the short as well as long term.”

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 180 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff who are the strength of the organization.

The Company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,40,000 doctors belonging to various specialties. Indoco has 10 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensiform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral, Rexitin, MCBM 69, Methycal, Dropizin, Noxa, Homide, Cal-Aid, Ninaf, Cital-Ui, Otorex, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:



Mr. Anuj Sonpal
Valorem Advisors
Tel: +91-22-4903-9500
Email:
indoco@valoremadvisors.com/corpcor@indoco.com